Clinical trial
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With…
NCT00005966 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00005966 |
|---|---|
| Title | Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, thalidomide |
| Start date | Oct 1, 2000 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 5, 2009 |
| Countries | Australia, Peru, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: